Literature DB >> 11796332

Discrepancy between uptake and intracellular activity of moxifloxacin in a Staphylococcus aureus-human THP-1 monocytic cell model.

Delphine Paillard1, Jean Grellet, Véronique Dubois, Marie-Claude Saux, Claudine Quentin.   

Abstract

The correlation between uptake of moxifloxacin by THP-1, a continuous line of monocytic cells devoid of intrinsic bactericidal properties, and its activity against Staphylococcus aureus ATCC 25923, a susceptible reference strain (MIC and minimal bactericidal concentration of moxifloxacin, 0.1 mg/liter), was studied in a 5-h assay. The uptake of the drug, added to the culture medium at 0.2 to 32 mg/liter, was evaluated by high-performance liquid chromatography. The ratio of the cellular to extracellular concentration of moxifloxacin reached, at equilibrium, 4.36 +/- 0.39 in uninfected cells and 6.25 +/- 0.41 in infected cells. The intracellular activity of moxifloxacin, introduced into the extracellular fluid at 0.06 to 8 mg/liter, was determined by the enumeration of viable bacteria. At concentrations < or =0.2 mg/liter, the drug inhibited only the intracellular bacterial growth, while at concentrations > or =0.5 mg/liter, it decreased the bacterial inoculum by less than 1 log(10) unit, with a maximum effect at 3 to 4 h, followed by regrowth of surviving bacteria to 80 to 120% of the original level at 5 h. In contrast, when killing curves were determined by using Mueller-Hinton broth with a similar inoculum (10(7) CFU/ml), moxifloxacin at concentrations > or =0.2 mg/liter reduced the inoculum by at least 3 log(10) units at 3 to 4 h, leaving < or =0.1% survival at 24 h. Persisters exhibited a fluoroquinolone susceptibility identical to that of S. aureus ATCC 25923. Our data indicate that moxifloxacin at therapeutic extracellular concentrations accumulates approximately sixfold in infected THP-1 cells and remains active intracellularly, but significantly less active than under in vitro conditions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11796332      PMCID: PMC127041          DOI: 10.1128/AAC.46.2.288-293.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  Intracellular microorganisms: a particular problem for chemotherapy. Introduction.

Authors:  H Hof
Journal:  Infection       Date:  1991       Impact factor: 3.553

2.  Comparative uptake of sparfloxacin and ciprofloxacin into human THP 1 monocytic cells.

Authors:  P Rispal; J Grellet; C Celerier; D Breilh; M Dorian; J L Pellegrin; M C Saux; B Leng
Journal:  Arzneimittelforschung       Date:  1996-03

3.  Uptake and intracellular activity of NM394, a new quinolone, in human polymorphonuclear leukocytes.

Authors:  M Ozaki; K Komori; M Matsuda; R Yamaguchi; T Honmura; Y Tomii; I Nishimura; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

Review 4.  Cellular transport of drugs.

Authors:  T H Steinberg
Journal:  Clin Infect Dis       Date:  1994-11       Impact factor: 9.079

5.  Effect of recombinant human gamma interferon on intracellular activities of antibiotics against Listeria monocytogenes in the human macrophage cell line THP-1.

Authors:  B Scorneaux; Y Ouadrhiri; G Anzalone; P M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

6.  Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia.

Authors:  P H Edelstein; M A Edelstein; J Ren; R Polzer; R P Gladue
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

7.  Uptake and intracellular activity of fleroxacin in phagocytic cells.

Authors:  T Yamamoto; H Kusajima; M Hosaka; H Shinoda
Journal:  Chemotherapy       Date:  1995 Sep-Oct       Impact factor: 2.544

8.  Uptake and intracellular activity of sparfloxacin in human polymorphonuclear leukocytes and tissue culture cells.

Authors:  I García; A Pascual; M C Guzman; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

9.  Intracellular penetration and activity of BAY Y 3118 in human polymorphonuclear leukocytes.

Authors:  I García; A Pascual; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

10.  Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages.

Authors:  N Mor; J Vanderkolk; L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

View more
  10 in total

1.  Contribution of Catalase and Superoxide Dismutase to the Intracellular Survival of Clinical Isolates of Staphylococcus aureus in Murine Macrophages.

Authors:  Debaditya Das; Biswadev Bishayi
Journal:  Indian J Microbiol       Date:  2011-01-25       Impact factor: 2.461

2.  Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection.

Authors:  Devyani Deshpande; Shashikant Srivastava; Claudia Meek; Richard Leff; Gerri S Hall; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

3.  Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages.

Authors:  Maritza Barcia-Macay; Cristina Seral; Marie-Paule Mingeot-Leclercq; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

4.  Influence of the protein kinase C activator phorbol myristate acetate on the intracellular activity of antibiotics against hemin- and menadione-auxotrophic small-colony variant mutants of Staphylococcus aureus and their wild-type parental strain in human THP-1 cells.

Authors:  Laetitia G Garcia; Sandrine Lemaire; Barbara C Kahl; Karsten Becker; Richard A Proctor; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2012-09-17       Impact factor: 5.191

5.  Plectasin shows intracellular activity against Staphylococcus aureus in human THP-1 monocytes and in a mouse peritonitis model.

Authors:  Karoline Sidelmann Brinch; Anne Sandberg; Pierre Baudoux; Françoise Van Bambeke; Paul M Tulkens; Niels Frimodt-Møller; Niels Høiby; Hans-Henrik Kristensen
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

6.  Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages.

Authors:  Cristina Seral; Françoise Van Bambeke; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

7.  Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations.

Authors:  Stéphane Carryn; Françoise Van Bambeke; Marie-Paule Mingeot-Leclercq; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

8.  Internalization of Staphylococcus aureus in lymphocytes induces oxidative stress and DNA fragmentation: possible ameliorative role of nanoconjugated vancomycin.

Authors:  Subhankari Prasad Chakraborty; Santanu Kar Mahapatra; Sumanta Kumar Sahu; Sabyasachi Das; Satyajit Tripathy; Sandeep Dash; Panchanan Pramanik; Somenath Roy
Journal:  Oxid Med Cell Longev       Date:  2011-09-18       Impact factor: 6.543

9.  Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics.

Authors:  Sreedhar Subramanian; Carol L Roberts; C Anthony Hart; Helen M Martin; Steve W Edwards; Jonathan M Rhodes; Barry J Campbell
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

10.  Intracellular Accumulation of Novel and Clinically Used TB Drugs Potentiates Intracellular Synergy.

Authors:  Lloyd Tanner; Gabriel T Mashabela; Charles C Omollo; Timothy J de Wet; Christopher J Parkinson; Digby F Warner; Richard K Haynes; Lubbe Wiesner
Journal:  Microbiol Spectr       Date:  2021-09-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.